Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Head and Neck Neoplasms 4cyclopia sequence 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Laryngeal Diseases 1Fatigue 1Depressive Disorder, Major 1Depression 1

Interventions

pembrolizumab 35Cetuximab 18Gemcitabine 14Nivolumab 13Cisplatin 13Paclitaxel 10Carboplatin 9Cyclophosphamide 7cemiplimab 6Fluorouracil 6Specimen Handling 5Magnetic Resonance Spectroscopy 5Docetaxel 5fludarabine 4durvalumab 4aldesleukin 4Immune Checkpoint Inhibitors 4Biopsy 4fludarabine phosphate 3Valproic Acid 3Radiation 3Interleukin-2 3Drug Therapy 3Bevacizumab 3130-nm albumin-bound paclitaxel 3tislelizumab 2sintilimab 2avelumab 2apatinib 2Tablets 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Sugars × Head & Neck × Clear all
NCT01427205 2013-04-05

Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡